Market Overview

Synteract's Francoise Desir Named to the PharmaVOICE 100 — The Most Inspiring People in Life Sciences

Share:

Respected team leader and motivator recognized for her passion and
dedication in bringing clinical trials to life

Synteract,
an innovative contract research organization (CRO) providing
full-service, Phase I-IV services enabling biopharma companies to bring
new medicines to market, congratulates Francoise Desir, project director
at Synteract, for being named one of the 2018
PharmaVOICE 100
. PharmaVOICE magazine releases the
list of the 100 most inspiring people in the life sciences industry
annually, identifying industry thought leaders and innovators who have
the biggest impact in their fields. This year marks the sixth that
Synteract leaders have made the list.

Francoise Desir inspires people daily as she makes improving people's
lives her mission, both personally and professionally. With more than a
decade of experience managing and helping global teams complete complex
drug development projects, she prioritizes the needs of her clients,
coordinating and managing clinical trials from start up through close
out.

Professionally, she exceeds expectations daily and is fueled by the
dedication and commitment of the colleagues and customers she works with
to develop needed treatments, as well as by the doctors and patients she
encounters who describe to her the positive impact they have witnessed
as a result of clinical research. In addition, from a personal
perspective, her most memorable vacation was to Africa to help a medical
clinic in need. She travelled with members of her family to donate
medical supplies, and other basic healthcare necessities. "We felt it
was a small act, but the impact was significant," Desir says.

"Francoise Desir is a respected and determined member of the Synteract
team. She's always focused on delivering a successful outcome to our
customers and on managing the complexities surrounding the global
clinical trials we undertake. She leads and inspires her team every day
as she demonstrates the passion and commitment she has to help others.
We congratulate her on this well-deserved award," said Steve Powell,
CEO. "Francoise embodies the spirit that helps us all bring clinical
trials to life, and we are very proud she is part of our Synteract team."

The PharmaVOICE 100 has become a hallmark for the life sciences
industry. Every year, thousands of nominations are submitted to PharmaVOICE
by colleagues who believe their nominee fits the required criteria of
providing inspiration to peers, coworkers, and companies through their
innovative and motivational approaches to addressing the industry's
challenges.

According to the magazine, "The PharmaVOICE 100 develop
breakthrough strategies, products and services. They are known for
pioneering new paths and lifting their companies to new heights. They
also take the time to mentor the next generation of industry leaders."
The full list of honorees is showcased in the August 2018 issue of the
magazine.

"As we move through life's journey, our days are quickly filled with
activity, most of it important in providing and caring for ourselves and
our families. I have learned that we have the capacity to stretch beyond
ourselves and that which consumes us day in and day out, and the reward
is greater to those who give than for those who receive," says Desir. "I
know what I do, what we all do in this industry, improves
lives…and my trip to Africa brought it full circle. We have the ability
to make a difference; each one of us CAN make a difference…we can change
lives."

About Synteract

With 800 staff members across 21 countries, Synteract
is an innovative, full-service contract research organization supporting
biopharmaceutical companies in all phases of clinical development to
help bring new medicines to market. Synteract has conducted nearly 4,000
studies on six continents and in more than 60 countries, working with
more than 26,000 investigative sites and nearly 750,000 patients. It has
contributed to more than 240 product approvals. The CRO offers a notable
depth of expertise in oncology, dermatology, and neuro degenerative
indications, as well as rare and orphan, pediatric, and immunotherapy
studies.

View Comments and Join the Discussion!